SRTA - NASDAQ

Strata Critical Medical, Inc.

SRTA·NASDAQ

$6.21

+1.5%

IndustrialsAirlines, Airports & Air Services

Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$537.33M

EPS0.5000

P/E Ratio12.42

Earnings Date08/04/2026

325.47M

Assets

27%

3Y-

5Y+1737.0%

10Y+18.0%

46.40M

Total Liabilities

34%

3Y-8.0%

5Y+599.0%

10Y-

279.07M

Total Equity

26%

3Y+2.0%

5Y+2419.0%

10Y-

Strata Critical Medical, Inc. Funding & Solvency Profile

SRTA · NASDAQ

Current Assets

Cash & Cash Equivalents30.97M

Net Receivables39.96M

Inventory0.00

Other Current Assets25.00M

Total Current Assets126 M

Non-Current Assets

Property, Plant & Equipment39.55M

Goodwill & Intangible Assets135.71M

Long-Term Investments0.00

Other Non-Current Assets24.02M

Total Non-Current Assets64 M

Total Assets

325.47M

Financial Health Analysis

Current Ratio

6.38x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.17x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

106 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

39% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Strata Critical Medical, Inc. Balance Sheet

SRTA • NASDAQ

Strata Critical Medical, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Sep 2021	Sep 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	31M	18.4M	27.9M	41.3M	2.6M	12.2M	0.0
Short-Term Investments	30.3M	108.8M	138.3M	150.7M	279.4M	0.0	276.3M
Cash & Short-Term Investments	61.2M	127.1M	166.1M	192.1M	282M	12.2M	276.3M
Net Receivables	40M	21.6M	21M	10.9M	5.5M	1.1M	0.0
Accounts Receivables	40M	21.6M	21M	10.9M	5.5M	1.1M	0.0
Inventory	0.0	0.0	0.0	0.0	547K	512K	0.0
Prepaids	0.0	0.0	0.0	12.1M	6.8M	499K	0.0
Other Current Assets	25M	12M	19.1M	3.1M	83K	114K	0.0
Total Current Assets	126.2M	160.7M	206.3M	218.1M	294.9M	14.4M	276.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	39.6M	39.8M	26.4M	19.7M	2.8M	2.5M	0.0
Goodwill	88.2M	41.1M	40.4M	39.4M	13.3M	0.0	0.0
Intangible Assets	47.5M	13.7M	20.5M	46.4M	24.4M	533K	0.0
Goodwill & Intangible Assets	135.7M	54.7M	60.9M	85.8M	37.7M	533K	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	200K	200K	0.0
Other Non-Current Assets	24M	1.4M	1.4M	1.4M	232K	107K	0.0
Total Non-Current Assets	199.3M	95.9M	88.7M	106.9M	40.9M	3.3M	0.0
Total Assets	325.5M	256.7M	294.9M	325M	335.9M	17.7M	276.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	0.0	0.0	16.5M	6.4M	776K	0.0
Accounts Payable	0.0	0.0	0.0	16.5M	6.4M	776K	0.0
Short Term Debt	652K	0.0	0.0	0.0	0.0	1.2M	0.0
Capital Lease Obligations (Current)	0.0	3.3M	4.8M	3.4M	438K	430K	0.0
Deferred Revenue	0.0	6.7M	6.8M	0.0	0.0	0.0	0.0
Other Current Liabilities	19.1M	12.8M	23.9M	6.7M	6M	4M	0.0
Total Current Liabilities	19.8M	22.7M	35.5M	26.6M	12.8M	6.3M	0.0
NON-CURRENT LIABILITIES
Long Term Debt	2.7M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	348K	185K	451K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	23.6M	5.8M	5M	9M	31.5M	0.0	0.0
Total Non-Current Liabilities	26.6M	12M	25.1M	23.9M	31.7M	291K	0.0
Capital Lease Obligations	0.0	9.3M	24.5M	18.3M	716K	721K	0.0
Total Liabilities	46.4M	34.7M	60.6M	50.5M	44.5M	6.6M	0.0
SHAREHOLDERS' EQUITY
Common Stock	7K	7K	7K	7K	7K	3K	0.0
Additional Paid-In Capital	0.0	407.1M	390.1M	375.9M	368.7M	48.2M	0.0
Retained Earnings	-145.6M	-186.9M	-159.8M	-103.7M	-76.4M	-37.1M	0.0
Accumulated Other Comprehensive Income/Loss	0.0	1.8M	4M	2.3M	-898K	0.0	0.0
Other Total Stockholders' Equity	424.6M	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	279.1M	221.9M	234.3M	274.5M	291.4M	11.1M	0.0
Total Equity	279.1M	221.9M	234.3M	274.5M	291.4M	11.1M	0.0
SUMMARY
Total Liabilities & Equity	325.5M	256.7M	294.9M	325M	335.9M	17.7M	276.3M
Total Investments	30.3M	108.8M	138.3M	150.7M	279.6M	200K	276.3M
Total Debt	3.3M	9.3M	24.5M	18.3M	716K	1.9M	0.0
Net Debt	-27.7M	-9.1M	-3.3M	-23M	-1.9M	-10.3M	0.0
Shares Outstanding	85,130,212	85,130,212	85,130,212	85,130,212	85,130,212	85,130,212	85,130,212

SEC Filings

SRTA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	May 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 14, 2026	May 28, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 05, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 02, 2025	2025	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	December 02, 2025	September 16, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing

Showing 1 to 10 of 99 filings

Related Guides

Blog Categories

Continue your SRTA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.